RecruitingPhase 1NCT06150157
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Studying Myeloproliferative neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Janssen Research & Development, LLC
- Principal Investigator
- Janssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC
- Intervention
- JNJ-88549968(drug)
- Enrollment
- 220 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- City of Hope, Duarte, California, United States
- UCHealth Cancer Care Anschutz Medical Campus University of Colorado Cancer Center, Aurora, Colorado, United States
- Moffit Cancer center, Tampa, Florida, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Levine Cancer Institute, Charlotte, North Carolina, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Sarah Cannon Cancer Institute, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada
- Jewish General Hospital, Montreal, Quebec, Canada
- Hopital Saint Louis, Paris, France
- CH LYON SUD - Hematology, Pierre-Bénite, France
- Universitaetsklinikum der RWTH Aachen, Aachen, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06150157 on ClinicalTrials.govOther trials for Myeloproliferative neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07441694Study of INCA036978 in Participants With Myeloproliferative NeoplasmsIncyte Corporation
- RECRUITINGPHASE2NCT07148947Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsUniversity of Washington
- RECRUITINGPHASE2NCT07228624Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesFred Hutchinson Cancer Center
- RECRUITINGNANCT07119970Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)University Hospital, Bordeaux
- RECRUITINGPHASE2NCT06661915A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)National Cancer Institute (NCI)
- RECRUITINGPHASE3NCT06468033P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskPharmaEssentia
- RECRUITINGNCT07165535Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology NetworkUniversity of Milano Bicocca
- RECRUITINGNANCT05745285Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareUniversity of Miami